Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
217.81
Dollar change
-0.25
Percentage change
-0.11
%
IndexNDX, S&P 500 P/E27.21 EPS (ttm)8.01 Insider Own0.76% Shs Outstand144.90M Perf Week-5.53%
Market Cap31.71B Forward P/E12.48 EPS next Y17.45 Insider Trans-0.11% Shs Float144.50M Perf Month7.58%
Income1.17B PEG6.89 EPS next Q3.98 Inst Own90.04% Short Float2.41% Perf Quarter-2.64%
Sales9.29B P/S3.42 EPS this Y6.14% Inst Trans0.82% Short Ratio2.83 Perf Half Y-5.81%
Book/sh104.48 P/B2.08 EPS next Y11.72% ROA4.56% Short Interest3.48M Perf Year-28.15%
Cash/sh7.38 P/C29.52 EPS next 5Y3.95% ROE8.04% 52W Range189.44 - 319.76 Perf YTD-15.83%
Dividend Est.- P/FCF- EPS past 5Y-18.05% ROI5.32% 52W High-31.88% Beta-0.03
Dividend TTM- Quick Ratio1.32 Sales past 5Y-4.53% Gross Margin68.31% 52W Low14.98% ATR (14)5.45
Dividend Ex-Date- Current Ratio2.10 EPS Y/Y TTM-62.75% Oper. Margin18.67% RSI (14)47.91 Volatility2.24% 2.54%
Employees7570 Debt/Eq0.46 Sales Y/Y TTM-2.49% Profit Margin12.56% Recom1.64 Target Price284.14
Option/ShortYes / Yes LT Debt/Eq0.44 EPS Q/Q0.93% Payout0.00% Rel Volume0.63 Prev Close218.06
Sales Surprise-0.80% EPS Surprise5.78% Sales Q/Q-5.62% EarningsApr 24 BMO Avg Volume1.23M Price217.81
SMA20-1.92% SMA502.26% SMA200-8.72% Trades Volume770,843 Change-0.11%
Date Action Analyst Rating Change Price Target Change
Feb-14-24Reiterated Needham Buy $305 → $300
Feb-14-24Downgrade Wells Fargo Overweight → Equal Weight $315 → $240
Jan-24-24Downgrade UBS Buy → Neutral $311 → $276
Dec-20-23Resumed Cantor Fitzgerald Overweight $311
Dec-07-23Upgrade Raymond James Mkt Perform → Outperform $283
Sep-06-23Initiated HSBC Securities Buy $360
Jul-27-23Initiated Scotiabank Sector Outperform $327
Jul-24-23Reiterated UBS Buy $346 → $335
May-01-23Upgrade Guggenheim Neutral → Buy $270 → $350
Apr-17-23Upgrade Piper Sandler Neutral → Overweight $280 → $346
Today 06:35AM
03:02AM
May-25-24 11:15PM
11:10PM
May-24-24 11:31AM
10:06AM Loading…
May-23-24 10:06AM
08:54AM
May-22-24 07:28PM
09:55AM
08:25AM
07:37AM
07:30AM
07:19AM
May-21-24 09:50AM
May-17-24 06:15AM
01:37PM Loading…
May-16-24 01:37PM
12:46PM
09:29AM
08:50AM
08:05AM
07:51AM
07:37AM
07:30AM
07:30AM
May-15-24 04:05PM
01:29PM
12:12PM
11:02AM
08:25AM
04:26AM
12:17AM Loading…
12:17AM
May-14-24 07:33PM
07:30PM
May-13-24 07:57PM
May-11-24 08:00AM
May-10-24 10:11AM
May-09-24 06:30AM
May-08-24 03:15PM
02:01PM
07:01AM
May-04-24 10:27AM
May-03-24 12:01PM
May-02-24 07:30AM
Apr-30-24 11:15AM
Apr-29-24 10:03AM
09:50AM
Apr-26-24 11:27AM
05:00AM
01:02AM
Apr-25-24 04:05PM
02:15PM
07:00AM
01:23AM
Apr-24-24 06:18PM
04:19PM
04:01PM
02:12PM
12:57PM
12:45PM
12:28PM
11:53AM
11:13AM
11:08AM
10:39AM
10:28AM
10:05AM
09:39AM
09:34AM
09:30AM
09:00AM
08:39AM
08:32AM
07:45AM
07:15AM
06:48AM
06:45AM
06:45AM
Apr-23-24 12:23AM
Apr-19-24 09:39AM
09:15AM
Apr-17-24 10:01AM
Apr-12-24 10:00AM
Apr-10-24 06:09PM
Apr-01-24 05:50PM
04:02PM
Mar-31-24 07:30PM
11:53AM
Mar-28-24 08:00AM
Mar-27-24 12:18PM
Mar-26-24 11:21AM
Mar-25-24 05:50PM
Mar-22-24 07:05AM
06:57AM
Mar-21-24 05:14PM
09:17AM
04:39AM
Mar-18-24 05:50PM
10:16AM
Mar-15-24 09:34AM
Mar-14-24 11:30AM
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Keeney AdamHead of Corporate DevelopmentMay 01 '24Option Exercise0.009380938May 03 08:00 PM
Singhal PriyaHead of DevelopmentApr 02 '24Sale213.099319,8174,886Apr 03 08:24 PM
Murphy NicoleHead of Pharm Ops and TechApr 01 '24Option Exercise0.0024009,751Apr 03 08:11 PM
Singhal PriyaHead of DevelopmentFeb 22 '24Sale221.2326257,9624,886Feb 26 07:54 PM
Singhal PriyaHead of DevelopmentFeb 16 '24Option Exercise0.001,20805,429Feb 21 09:27 PM
ALEXANDER SUSAN HEVP Chief Legal OfficerFeb 16 '24Option Exercise0.005,037052,506Feb 21 09:39 PM
Gregory GingerEVP, Human ResourcesFeb 16 '24Option Exercise0.004,704014,341Feb 21 09:36 PM
Izzar RachidHead of Global Product Strat.Feb 16 '24Option Exercise0.002,017010,014Feb 21 09:33 PM
Kramer RobinChief Accounting OfficerFeb 16 '24Option Exercise0.001,34506,354Feb 21 09:31 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerFeb 16 '24Option Exercise0.006,720020,692Feb 21 09:29 PM
Murphy NicoleHead of Pharm Ops and TechFeb 16 '24Option Exercise0.001,26009,624Feb 21 09:28 PM
Singhal PriyaHead of DevelopmentFeb 16 '24Sale221.4910823,9215,148Feb 21 09:27 PM
Rowinsky Eric KDirectorFeb 15 '24Buy222.54455101,25620,629Feb 20 09:13 PM
Singhal PriyaHead of DevelopmentFeb 12 '24Sale239.45419100,3304,516Feb 13 06:06 PM
Singhal PriyaHead of DevelopmentFeb 09 '24Option Exercise0.001,21205,309Feb 13 06:06 PM
Murphy NicoleHead of Pharm Ops and TechFeb 09 '24Option Exercise0.002,27209,529Feb 13 06:04 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerFeb 09 '24Option Exercise0.003,257017,555Feb 13 06:03 PM
Kramer RobinChief Accounting OfficerFeb 09 '24Option Exercise0.0083305,523Feb 13 06:01 PM
Gregory GingerEVP, Human ResourcesFeb 09 '24Option Exercise0.002,158011,778Feb 13 06:14 PM
ALEXANDER SUSAN HEVP Chief Legal OfficerFeb 09 '24Option Exercise0.002,575050,021Feb 13 05:56 PM
Izzar RachidHead of Global Product Strat.Feb 09 '24Option Exercise0.001,51509,081Feb 13 06:00 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerFeb 08 '24Option Exercise0.002,335015,063Feb 09 08:03 PM
Murphy NicoleHead of Pharm Ops and TechFeb 08 '24Option Exercise0.002,10107,895Feb 09 08:01 PM
Kramer RobinChief Accounting OfficerFeb 08 '24Option Exercise0.0078804,943Feb 09 08:06 PM
Gregory GingerEVP, Human ResourcesFeb 08 '24Option Exercise0.001,635010,118Feb 09 08:14 PM
Izzar RachidHead of Global Product Strat.Feb 08 '24Option Exercise0.002,04308,187Feb 09 08:11 PM
ALEXANDER SUSAN HEVP Chief Legal OfficerFeb 08 '24Option Exercise0.002,190048,101Feb 09 08:16 PM
Singhal PriyaHead of DevelopmentFeb 02 '24Sale245.93634155,9204,097Feb 05 06:38 PM
Singhal PriyaHead of DevelopmentFeb 01 '24Option Exercise0.001,82805,292Feb 05 06:38 PM
Singhal PriyaHead of DevelopmentDec 11 '23Sale248.0011027,2803,464Dec 12 05:06 PM
Kramer RobinChief Accounting OfficerDec 08 '23Option Exercise0.0035104,325Dec 12 05:02 PM
Singhal PriyaHead of DevelopmentDec 08 '23Option Exercise0.0042603,780Dec 12 05:06 PM
BIOGEN INC.10% OwnerSep 26 '23Sale0.506,000,0003,000,00017,652,466Sep 28 05:30 PM
Singhal PriyaHead of DevelopmentSep 05 '23Sale269.43431116,1243,354Sep 06 06:06 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerSep 01 '23Option Exercise0.005,285014,060Sep 06 06:08 PM
Singhal PriyaHead of DevelopmentSep 01 '23Option Exercise0.001,66804,592Sep 06 06:06 PM
Singhal PriyaHead of DevelopmentJul 03 '23Sale282.878122,9122,924Jul 05 05:33 PM
Singhal PriyaHead of DevelopmentJun 30 '23Option Exercise0.0031503,158Jul 05 05:33 PM
Izzar RachidHead of Global Product Strat.Jun 30 '23Option Exercise0.0050406,388Jul 05 05:37 PM
Kramer RobinChief Accounting OfficerJun 30 '23Option Exercise0.0025204,096Jul 05 05:35 PM